The introduction of five new injectable products by Baxter International Inc. is likely to have a positive impact on its stock price in the short term. This expansion not only enhances Baxter's pharmaceuticals portfolio but also aligns with the growing demand for ready-to-use medical formulations, which can improve patient safety and operational efficiency in healthcare settings. The focus on critical therapeutic areas further underscores the strategic importance of these launches, potentially leading to increased market share and revenue growth in the pharmaceutical sector.